Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Medical Solutions Group Regulatory News (AMS)

Share Price Information for Advanced Medical Solutions Group (AMS)

Share Price is delayed by 15 minutes
Get Live Data
218.00    -3.00 (-1.36%)
Bid:
217.50
Ask:
218.50
Spread: 1.00 (0.46%)
Market Cap: £473.56m
AMS Live PriceLast checked at - London Stock Exchange

Intraday Advanced Medical Solutions Group Share Chart

AGM Statement

20 May 2014 07:00

RNS Number : 5053H
Advanced Medical Solutions Grp PLC
20 May 2014
 



 

20 May 2014

 

Advanced Medical Solutions Group plc

("AMS")

 

Annual General Meeting

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will hold its Annual General Meeting ("AGM") at 11.00 today at the offices of Tavistock Communications, 131 Finsbury Pavement, London, EC2A 1NT.

 

Chris Meredith, AMS's Chief Executive Officer, will give a presentation at the AGM, the slides from which will be made available on the Company's website www.admedsol.com. No new material information will be provided.

 

In line with last year's practice, AMS will be providing an update on trading in late June.

 

- ends -

 

For further information, please contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

 

 

 

Tavistock Communications

Tel: +44 (0) 20 7920 3150

John West / Chris Munden / Andrew Dunn

 

 

 

Investec Bank plc

Tel: +44 (0) 20 7597 5970

Daniel Adams

 

 

About Advanced Medical Solutions Group plc - see www.admedsol.com 

 

Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$15 billion global wound care market. Through a mix of organic development and a number of acquisitions, AMS now has a wide range of products based on technologies that include alginates, silver alginates, foams, collagens, cyanoacrylate adhesives and sutures.

 

AMS manufactures wound care products for an extensive list of Original Equipment Manufacturer ("OEM") customers around the world, but the majority of the Group's revenues now come from its own brands - ActivHeal® wound care products in the UK to the NHS, LiquiBand® cyanoacrylate products primarily in the UK, Europe and the USA, and RESORBA® sutures and collagen wound care products primarily in Europe. AMS develops innovative products from its R&D pipeline which it commercialises globally, either directly or through partnerships with its OEM customers.

 

AMS's products are sold globally via a network of regional or multinational partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.

 

With 450 employees operating under four distinct business units (Branded Direct, Branded Distributed, OEM and Bulk Materials) that match its multiple products and routes-to-market, AMS's products are manufactured from two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMSFAFIUFLSESI
Date   Source Headline
10th Mar 20207:00 amRNSFDA Approval of LiquiBand® Rapid(TM)
11th Feb 202010:03 amRNSHolding(s) in Company
15th Jan 20207:00 amRNSYear End Trading Update
31st Dec 201912:18 pmRNSTotal Voting Rights
2nd Dec 20197:00 amRNSAcquisition of Biomatlante SA
29th Nov 20193:08 pmRNSTotal Voting Rights
29th Nov 20197:00 amRNSThird party sterilisation failure
31st Oct 20193:13 pmRNSTotal Voting Rights
31st Oct 20193:09 pmRNSHolding(s) in Company
16th Sep 201911:15 amRNSHolding(s) in Company
16th Sep 20197:00 amRNSDirector/PDMR Shareholding
11th Sep 20197:00 amRNSInterim Results
6th Sep 20197:00 amRNSBlock listing Interim Review
8th Aug 20197:00 amRNSNotice of Interim Results
31st Jul 20195:52 pmRNSTotal Voting Rights
30th Jul 20197:00 amRNSFDA approval for two advanced woundcare ranges
28th Jun 20192:23 pmRNSTotal Voting Rights
21st Jun 20197:00 amRNSTrading Update
5th Jun 20195:29 pmRNSResult of AGM
5th Jun 20197:00 amRNSNotice of AGM
31st May 20193:10 pmRNSTotal Voting Rights
14th May 20197:00 amRNSIDE received for LiquiBand Fix8 in US
30th Apr 20194:56 pmRNSTotal Voting Rights
30th Apr 20199:40 amRNSNotice of Annual General Meeting and Annual Report
29th Apr 20195:27 pmRNSDirector/PDMR Shareholding
4th Apr 201910:16 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSHolding(s) in Company
13th Mar 20197:00 amRNSUnaudited preliminary results
6th Mar 20199:13 amRNSBlock listing Interim Review
4th Mar 20192:24 pmRNSHolding(s) in Company
19th Feb 20197:00 amRNSNotice of Results
12th Feb 20194:23 pmRNSHolding(s) in Company
31st Jan 20197:00 amRNSAcquisition of Sealantis
31st Dec 20187:00 amRNSManagement Change
31st Dec 20187:00 amRNSTotal Voting Rights
20th Dec 20187:00 amRNSFix8 approved in Europe
18th Dec 20187:00 amRNSTrading Update
30th Nov 20181:40 pmRNSTotal Voting Rights
9th Nov 20183:06 pmRNSHoldings in Company
6th Nov 20184:33 pmRNSApplication for Admission
2nd Nov 201811:13 amRNSHolding(s) in Company
31st Oct 20185:20 pmRNSTotal Voting Rights
17th Sep 20184:30 pmRNSHolding(s) in Company
12th Sep 20187:00 amRNSInterim Results
31st Aug 20184:08 pmRNSApplication for Admission
10th Aug 20187:00 amRNSFDA approval for two woundcare portfolio dressings
7th Aug 20185:22 pmRNSHoldings in Company
27th Jul 20187:00 amRNSNotice of Interim Results
26th Jul 20183:23 pmRNSHoldings in Company
25th Jul 20182:26 pmRNSHoldings in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.